What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

1. [European journal of nuclear medicine and molecular imaging · 2025
   Trial
2. Application of theranostics in thyroid cancer management.The Journal of clinical endocrinology and metabolism · 2026
   Review
3. Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review.Cancers · 2026
   Review
4. Future of radiotheranostics.BMJ oncology · 2026
   Review
5. How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.Drugs in context · 2026
   Review
6. Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2025
   Observational
7. Current and Emerging Radiotracers and Technologies for Detection of Advanced Differentiated Thyroid Cancer: A Narrative Review.Cancers · 2025
   Review
8. Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.Pharmaceuticals (Basel, Switzerland) · 2024
   Review
9. Match Point: Nuclear Medicine Imaging for Recurrent Thyroid Cancer in TENIS Syndrome-Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024
   Review
10. Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer.Current oncology (Toronto, Ont.) · 2024
    Review
11. Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer.Cancers · 2024
    Review
12. Expression of integrin αFuture oncology (London, England) · 2024
    Article
13. Evaluation of integrin αCancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Article
14. Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Review
15. The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization.Frontiers in bioengineering and biotechnology · 2022
    Article
16. Nephrotoxicity after radionuclide therapies.Translational oncology · 2022
    Article
17. Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.Frontiers in oncology · 2022
    Review
18. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.Frontiers in endocrinology · 2022
    Review
19. Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.Frontiers in endocrinology · 2022
    Review
20. Next-Generation Molecular Imaging of Thyroid Cancer.Cancers · 2021
    Review

Corrections and comments

• Commented on by
  Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine.2020

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as